 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | doxorubicin hydrochloride / Generic mfg.
Journal: Beneficial Effects of Oral Carbon Monoxide on Doxorubicin-Induced Cardiotoxicity. (Pubmed Central) - May 7, 2024
These findings strongly support using HBI-002 as a cardioprotective agent that maintains the therapeutic benefits of doxorubicin cancer treatment while mitigating cardiac damage.
- carbon monoxide (HBI-002) / Hillhurst Biopharma
New P1/2 trial: A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD) (clinicaltrials.gov) - Nov 22, 2023
P1/2, N=8, Not yet recruiting, Sponsor: Hillhurst Biopharmaceuticals, Inc.
- || carbon monoxide (HBI-002) / Hillhurst Biopharma
Trial completion, Trial primary completion date: A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers (clinicaltrials.gov) - Jul 20, 2023
P1, N=20, Completed, Sponsor: Hillhurst Biopharmaceuticals, Inc.
These findings strongly support using HBI-002 as a cardioprotective agent that maintains the therapeutic benefits of doxorubicin cancer treatment while mitigating cardiac damage. Recruiting --> Completed | Trial primary completion date: Jan 2023 --> Apr 2023
- carbon monoxide (HBI-002) / Hillhurst Biopharma
Low Dose Carbon Monoxide Is Neuroprotective in Models of Parkinson's Disease (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3823;
HBI-002 upregulated heme oxygenase-1, HIF-1a, and cathepsin D. In the rotenone model, treatment with low dose CO reduced cell death. Conclusions These results demonstrating reduced cell death and aSyn pathology in animal and cell models support the therapeutic potential of low dose CO for PD.
- || carbon monoxide (HBI-002) / Hillhurst Biopharma
Enrollment open, Trial completion date, Trial primary completion date: A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers (clinicaltrials.gov) - Oct 4, 2022
P1, N=20, Recruiting, Sponsor: Hillhurst Biopharmaceuticals, Inc.
Conclusions These results demonstrating reduced cell death and aSyn pathology in animal and cell models support the therapeutic potential of low dose CO for PD. Not yet recruiting --> Recruiting | Trial completion date: Oct 2022 --> Feb 2023 | Trial primary completion date: Sep 2022 --> Jan 2023
- carbon monoxide (HBI-002) / Hillhurst Biopharma
Ameliorative role of low-dose carbon monoxide exposure in an animal model of parkinsons disease. () - Jun 16, 2022 - Abstract #CANACN2022CAN_ACN_338;
Not yet recruiting --> Recruiting | Trial completion date: Oct 2022 --> Feb 2023 | Trial primary completion date: Sep 2022 --> Jan 2023 - Our findings suggest that a low-dose carbon monoxide could be a neuroprotective therapy for Parkinson's disease.
- carbon monoxide (HBI-002) / Hillhurst Biopharma
CARBON MONOXIDE AT LOW DOSES REDUCES DOPAMINE CELL LOSS AND ALPHA-SYNUCLEIN PATHOLOGY IN MODELS OF PARKINSON’S DISEASE (ONSITE: 113) - Dec 17, 2021 - Abstract #ADPD2022ADPD_603;
- Our findings suggest that a low-dose carbon monoxide could be a neuroprotective therapy for Parkinson's disease. These results demonstrating reduced dopamine cell death and aSyn pathology advance low dose CO as a potential neuroprotective strategy for PD.
- | carbon monoxide (HBI-002) / Hillhurst Biopharma
Trial completion date, Trial primary completion date: A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers (clinicaltrials.gov) - Dec 15, 2021
P1, N=20, Not yet recruiting, Sponsor: Hillhurst Biopharmaceuticals, Inc.
These results demonstrating reduced dopamine cell death and aSyn pathology advance low dose CO as a potential neuroprotective strategy for PD. Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- doxorubicin hydrochloride / Generic mfg.
[VIRTUAL] Effects of Oral Carbon Monoxide on Doxorubicin-Induced Cardiotoxicity (ePosters) - Sep 24, 2021 - Abstract #AHA2021AHA_2056;
Introduction : Doxorubicin (DOX) and other anthracyclines comprise important anticancer drugs. Collectively, these findings support HBI-002 as a promising cardioprotective agent against DOX toxicity and warrant further development as a therapeutic.
- | carbon monoxide (HBI-002) / Hillhurst Biopharma
Trial completion date, Trial primary completion date: A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers (clinicaltrials.gov) - Feb 12, 2021
P1, N=20, Not yet recruiting, Sponsor: Hillhurst Biopharmaceuticals, Inc.
Collectively, these findings support HBI-002 as a promising cardioprotective agent against DOX toxicity and warrant further development as a therapeutic. Trial completion date: May 2020 --> Oct 2021 | Trial primary completion date: Feb 2020 --> Sep 2021
- carbon monoxide (HBI-002) / Hillhurst Biopharma, HB-002 / Zhejiang Huahai Pharma, HB-002 M / Zhejiang Huahai Pharma
[VIRTUAL] NEUROPROTECTION OF LOW DOSE CARBON MONOXIDE IN GENETIC AND TOXIN MODELS OF PARKINSON’S DISEASE () - Dec 24, 2020 - Abstract #ADPD2021ADPD_1363;
Low-dose CO protects nigral dopamine neurons, preserves striatal dopamine content, and reduces aSyn pathology in animal models of PD. Low dose CO may have disease-modifying activity in PD.
- | carbon monoxide (HBI-002) / Hillhurst Biopharma
New P1 trial: A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers (clinicaltrials.gov) - Apr 24, 2019
P1, N=28, Not yet recruiting, Sponsor: Hillhurst Biopharmaceuticals, Inc.